medRxiv · 2022 · 12 citations · 60 references
Life SciencesImmunologyInfectious DiseasesAgingAutoimmunityImmunopathologyAutoantibodiesAutoantibody-mediated DiseaseAutoantigensAutoimmune BiomarkersAutoimmune Disease PathogenesisAutoimmune DiseasesAging-related ImmunosuppressionAutoantibody BiomarkersAutoantibody GenerationAutoantibody PathogenesisNatural AutoantibodiesPathogenic AutoantibodiesPlatelet AutoantibodiesSars-cov-2 Infection
ABSTRACT Age is a significant risk factor for the coronavirus disease 2019 (COVID-19) outcomes due to immunosenescence and certain age-dependent medical conditions (e.g., obesity, cardiovascular disorder, diabetes, chronic respiratory disease). However, despite the well-known influence of age on autoantibody biology in health & disease, its impact on the risk of developing severe COVID-19 remains poorly explored. Here, we performed a cross-sectional study of autoantibodies directed against 58 targets associated with autoimmune diseases in 159 individuals with different COVID-19 outcomes (with 71 mild, 61 moderate, and 27 severe patients) and 73 healthy controls. We found that the natural production of autoantibodies increases with age and is exacerbated by SARS-CoV-2 infection, mostly in severe COVID-19 patients. Multivariate regression analysis showed that severe COVID-19 patients have a significant age-associated increase of autoantibody levels against 16 targets (e.g., amyloid β peptide, β catenin, cardiolipin, claudin, enteric nerve, fibulin, insulin receptor a, and platelet glycoprotein). Principal component analysis with spectrum decomposition based on these autoantibodies indicated an age-dependent stratification of severe COVID-19 patients. Random forest analysis ranked autoantibodies targeting cardiolipin, claudin, and platelet glycoprotein as the three most crucial autoantibodies for the stratification of severe elderly COVID-19 patients. Follow-up analysis using binomial regression found that anti-cardiolipin and anti-platelet glycoprotein autoantibodies indicated a significantly increased likelihood of developing a severe COVID-19 phenotype, presenting a synergistic effect on worsening COVID-19 outcomes. These findings provide new key insights to explain why elderly patients less favorable outcomes have than young individuals, suggesting new associations of distinct autoantibody levels with disease severity.
60
<i>circlize</i>implements and enhances circular visualization in R
Zuguang Gu, Lei Gu, Roland Eils et al. · Bioinformatics · 2014 · 4.6K citations · Full text
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Paul Bastard, Lindsey B. Rosen, Qian Zhang et al. · Science · 2020 · 2.8K citations · Full text
What is principal component analysis?
Markus Ringnér · Nature Biotechnology · 2008 · 2.5K citations